Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.

Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, Mitsudomi T, Haber DA.

Clin Cancer Res. 2008 Jul 1;14(13):4079-84. doi: 10.1158/1078-0432.CCR-07-5030.

2.
3.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.

Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12. Review.

4.

Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.

Calvo E, Baselga J.

J Clin Oncol. 2006 May 10;24(14):2158-63. Review.

PMID:
16682734
5.

EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.

Yang CH.

Lung Cancer. 2008 Jun;60 Suppl 2:S23-30. doi: 10.1016/S0169-5002(08)70102-8. Review.

PMID:
18513581
6.

Association of epidermal growth factor receptor (EGFR) gene polymorphism with lung cancer risk: a systematic review.

Feng X, Qin JJ, Zheng BS, Huang LL, Xie XY, Zhou HF.

J Recept Signal Transduct Res. 2014 Oct;34(5):333-4. doi: 10.3109/10799893.2014.885052. Epub 2014 Feb 4. Review.

PMID:
24495289
Items per page

Supplemental Content

Write to the Help Desk